 Protein Kinase Inhibitors
"Protein Kinase Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents that inhibit PROTEIN KINASES.
| Descriptor ID |
D047428
|
| MeSH Number(s) |
D27.505.519.389.755
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Protein Kinase Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Protein Kinase Inhibitors".
This graph shows the total number of publications written about "Protein Kinase Inhibitors" by people in this website by year, and whether "Protein Kinase Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 2 | 2 | | 1997 | 0 | 1 | 1 | | 1999 | 0 | 1 | 1 | | 2003 | 0 | 1 | 1 | | 2004 | 0 | 4 | 4 | | 2005 | 3 | 3 | 6 | | 2006 | 6 | 7 | 13 | | 2007 | 10 | 4 | 14 | | 2008 | 6 | 11 | 17 | | 2009 | 7 | 6 | 13 | | 2010 | 19 | 12 | 31 | | 2011 | 10 | 8 | 18 | | 2012 | 17 | 10 | 27 | | 2013 | 27 | 13 | 40 | | 2014 | 23 | 14 | 37 | | 2015 | 24 | 14 | 38 | | 2016 | 20 | 16 | 36 | | 2017 | 17 | 11 | 28 | | 2018 | 31 | 18 | 49 | | 2019 | 28 | 21 | 49 | | 2020 | 10 | 14 | 24 | | 2021 | 14 | 16 | 30 | | 2022 | 7 | 28 | 35 | | 2023 | 0 | 25 | 25 | | 2024 | 6 | 19 | 25 | | 2025 | 19 | 6 | 25 | | 2026 | 16 | 4 | 20 |
To return to the timeline, click here.
Below are the most recent publications written about "Protein Kinase Inhibitors" by people in Profiles.
-
Kar A, Banerjee T, Pozdeyev N, Holmstoen TB, Foust LJ, Bagby SM, Pitts TM, Habra MA, Wierman ME, Kiseljak-Vassiliades K. Comprehensive profiling of OTSSP167 action in adrenocortical carcinoma. Endocrinology. 2026 Sep 03; 167(10).
-
Le X, Passaro A, Zhao Y, Huang Y, Laskin J, Rodriguez-Abreu D, Calles A, Bazhenova L, Lo Russo G, Leighl NB, Cappuzzo F, Girard N, Popat S, Fang W, Luo Y, Li W, He Z, Zhao H, Li M, Song Q, Zhao H, El Darsa H, Monnet I, Cobo Dols M, García Campelo R, Jotte R, Berz D, Spira A, Pérol M, Nagasaka M, West H, Styles L, Li J, Clow F, Goldman J, Zhang L. Ivonescimab plus chemotherapy versus placebo plus chemotherapy in patients with advanced EGFR-mutated non-small-cell lung cancer after disease progression on EGFR tyrosine kinase inhibitor therapy (HARMONi): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2026 Sep; 27(9):1094-1109.
-
Stacchiotti S, Blay JY, Rutkowski P, Gelderblom H, Falcón A, Le Cesne A, Desai J, Palmerini E, Serrano C, Ganjoo KN, D'Amato GZ, Ryan CW, Wilky BA, Ferraresi V, Saleh R, Ravi V, Razak AA, Herráez AC, Ahmed M, Bernthal NM, van de Sande M, Brahmi M, Szostakowski B, Sen J, Zeringo NA, Harrow B, Narasimhan S, Saunders A, Sharma MG, Sherman ML, Wagner AJ, Tap WD. Vimseltinib for patients with tenosynovial giant cell tumor: A multicenter, open-label, phase 2 trial. Cancer. 2026 Sep 01; 132(17):e70564.
-
Zelenetz AD, Gordon LI, Abramson JS, Advani RH, Altahan A, Andreadis B, Bartlett NL, Budde LE, Caimi PF, DeVos S, Dholaria B, Fayad LE, Gaballa S, Habermann TM, Hernandez-Ilizaliturri F, Hu B, Kamdar M, Karimi Y, Kelsey CR, King R, Kline J, Krivacic S, LaCasce AS, Landsburg D, Lim M, Messmer M, Pophali P, Rabinovitch R, Ramakrishnan P, Reid E, Riedell P, Roberts KB, Saha A, Saito NG, Sawalha Y, Smith SD, Swinnen LJ, Tuscano J, Vose JM, Dwyer M, Sundar H. B-Cell Lymphomas, Version 4.2026, NCCN Clinical Practice Guidelines In Oncology. J Natl Compr Canc Netw. 2026 Sep; 24(9).
-
Budde LE, Kamdar M, Assouline SE, Chavez JC, Ghosh N, Ollila TA, Hodson DJ, Modi D, Bastos-Oreiro M, Naik SG, Nakhoda SK, Lee Batlevi C, Wang J, Makadia S, Kwan A, Penuel E, Jing J, Wu H, Ead W, Pham S, To I, Wei MC, Wang ML. Mosunetuzumab plus polatuzumab vedotin for relapsed/refractory MCL after BTK inhibitor therapy: a phase 2 study. Blood. 2026 Aug 06; 148(6):682-692.
-
Contreras-Zárate MJ, Jaramillo-Gómez JA, Marquez-Ortiz RA, Pham TC, Koliavas SN, Ormond DR, Navarro AC, Nemenoff RA, Camidge DR, Cittelly DM. Targeting Wild-type NTRK in NTRK Fusion-Negative Lung Cancer Decreases Brain Metastases. Cancer Res Commun. 2026 Aug 01; 6(8):1850-1861.
-
Espinoza-Gutarra MR, Jarret B, Wang X, Afghahi A, Bae S. Real-World Outcomes of Acute Myeloid Leukemia Patients Undergoing Treatment With Tyrosine Kinase Inhibitor (TKI) Therapy Targeting FLT3, IDH1, or IDH2. Cancer Rep (Hoboken). 2026 08; 9(8):e70657.
-
Kartika T, Buitrago L, Li J, Cunningham-Rundles C, Coller BS. Comparison of variably specific Bruton tyrosine kinase inhibitors on platelet aggregation mediated by Fc? receptor (Fc?R) IIa, glycoprotein VI, and platelet endothelial aggregation receptor (PEAR) 1: implications for Bruton tyrosine kinase inhibitors as antithrombotic therapy. Res Pract Thromb Haemost. 2026 Jul; 10(5):106841.
-
Yamamoto TM, Iwanaga R, Woodruff ER, Elder AM, Petkov A, Nurmemmedov E, Eisenmesser E, Reigan P, Bitler BG, Brubaker LW. Chromobox 2 Inhibition: A Novel Activity of Alisertib, an Aurora A Kinase Inhibitor. Mol Cancer Ther. 2026 Jul 02; 25(7):1130-1143.
-
Deterding R, Young LR, DeBoer EM, Warburton D, Cunningham S, Schwerk N, Brown KK, Koucký V, Weinman JP, Simmons J, Dumistracel M, Jantzen F, Gahlemann M, Griese M. Continued Nintedanib Treatment in Children and Adolescents With Fibrosing ILDs: Data From InPedILD-ON. Pediatr Pulmonol. 2026 Jun; 61(6):e71707.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|